NCT04182581 - A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 15, 2019

Primary Completion Date

September 30, 2020

Study Completion Date

May 31, 2021

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL

BCMA/CD19 Dual-Target CAR-T

BCMA/CD19 Dual-Target CAR-T target both BCMA and CD19. The subjects will receive CAR-T as one dose. The dosage ranges from 5×10\^4 to 3×10\^5 CAR+T/Kg.

Trial Locations (1)

710000

RECRUITING

First affiliated hospital of air force military medical university(i.e., Xijing Hopital), Xi’an